Artivion (NYSE:AORT) SVP Marshall Stanton Sells 2,423 Shares

Artivion, Inc. (NYSE:AORT) SVP Marshall Stanton sold 2,423 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $37.59, for a total value of $91,080.57. Following the sale, the senior vice president owned 43,180 shares in the company, valued at $1,623,136.20. The trade was a 5.31% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Artivion Price Performance

AORT stock traded up $0.31 during mid-day trading on Wednesday, hitting $35.66. 300,261 shares of the stock were exchanged, compared to its average volume of 399,410. The business has a fifty day moving average price of $42.51 and a 200 day moving average price of $43.14. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.25. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. The stock has a market capitalization of $1.71 billion, a price-to-earnings ratio of 178.32 and a beta of 1.59.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. The company had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.Artivion’s quarterly revenue was up 19.2% on a year-over-year basis. On average, sell-side analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Investors Weigh In On Artivion

Several institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada raised its holdings in Artivion by 107.0% in the 1st quarter. Royal Bank of Canada now owns 38,707 shares of the company’s stock worth $952,000 after purchasing an additional 20,010 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Artivion by 8.8% during the 1st quarter. AQR Capital Management LLC now owns 35,053 shares of the company’s stock valued at $862,000 after purchasing an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company’s stock valued at $580,000 after buying an additional 1,032 shares during the period. Oppenheimer Asset Management Inc. bought a new position in Artivion in the second quarter worth about $669,000. Finally, Envestnet Asset Management Inc. lifted its holdings in Artivion by 364.4% in the second quarter. Envestnet Asset Management Inc. now owns 52,871 shares of the company’s stock worth $1,644,000 after buying an additional 41,487 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on AORT shares. Canaccord Genuity Group cut their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Citizens Jmp lifted their target price on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $58.00 price objective on shares of Artivion in a research note on Monday, February 2nd. Finally, Oppenheimer reiterated an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a report on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $48.97.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.